Thomas A Macek|TA Macek, Thomas Macek, T Macek

Thomas A Macek|TA Macek, Thomas Macek, T Macek

Novartis Institutes for BioMedical Research - Bhubaneswar / United States
Medical and Health Sciences / Psychiatry
AD Scientific Index ID: 4383367
-
person_outline Thomas A Macek|TA Macek, Thomas Macek, T Macek's MOST POPULAR ARTICLES
1-) Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm …JW Day, RS Finkel, CA Chiriboga, AM Connolly, TO Crawford, BT Darras, ...The Lancet Neurology 20 (4), 284-293, 20212522021
2-) A 3‐week, randomized, placebo‐controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed statesRS McIntyre, M Cohen, J Zhao, L Alphs, TA Macek, J PanagidesBipolar disorders 11 (7), 673-686, 20092462009
3-) Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trialRS McIntyre, M Cohen, J Zhao, L Alphs, TA Macek, J PanagidesJournal of affective disorders 122 (1-2), 27-38, 20102092010
4-) Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trialKA Strauss, MA Farrar, F Muntoni, K Saito, JR Mendell, L Servais, ...Nature medicine 28 (7), 1381-1389, 20222132022
5-) Differential involvement of group II and group III mGluRs as autoreceptors at lateral and medial perforant path synapsesTA Macek, DG Winder, RW Gereau 4th, CO Ladd, PJ ConnJournal of neurophysiology 76 (6), 3798-3806, 19962121996